secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001804220-21-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q2 revenue up 163% to $5.14B; GAAP EPS $27.97; EYLEA sales record $1.42B
--------------------------------------------------------------------------------

- Total revenues $5.14B (+163% YoY) including $2.59B REGEN-COV; core revenue ex-REGEN-COV +22%.
- GAAP diluted EPS $27.97 vs $7.61 in Q2 2020; non-GAAP diluted EPS $25.80 vs $7.16.
- EYLEA US net sales record $1.42B (+28% YoY); Dupixent global net sales $1.50B (+59% YoY, recorded by Sanofi).
- REGEN-COV: $2.59B US sales from 1.25M doses; EUA expanded for prophylaxis; Japan full approval; RECOVERY trial showed 20% mortality reduction in seronegative.
- Pipeline: Dupixent Phase 3 CSU positive; Libtayo Phase 3 NSCLC stopped early for survival benefit; $1.8B Tarrytown campus expansion over 6 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422021000023/0001804220-21-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422021000023/regn-20210805.htm
  HTML page:      https://secwatch.observer/filing/0001804220-21-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer